Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ.
about
Structures of human Golgi-resident glutaminyl cyclase and its complexes with inhibitors reveal a large loop movement upon inhibitor bindingDiverse molecular targets for therapeutic strategies in Alzheimer's diseaseNatural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development.Glutaminyl cyclase knock-out mice exhibit slight hypothyroidism but no hypogonadism: implications for enzyme function and drug developmentThe Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42.Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.Pyroglutamate-amyloid-β and glutaminyl cyclase are colocalized with amyloid-β in secretory vesicles and undergo activity-dependent, regulated secretion.Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process.Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanismsIsoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease.Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer diseaseIdentification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening.Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse modelsMolecular characterization of tick salivary gland glutaminyl cyclase.pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity.Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.Mammalian glutaminyl cyclases and their isoenzymes have identical enzymatic characteristics.Characterization of AβpN3 deposition in the brains of dogs of various ages and other animal species.
P2860
Q24338927-7CC0F940-72AF-4CEB-9D75-8CCADBF9E718Q26827193-E40A7FE3-4551-4420-BEEB-CB8EE485D940Q30313757-20947BCA-490E-4559-BF16-328248D1FA50Q30317993-67095D2C-54F8-4DC1-BF15-59456616874DQ30318462-54522B9C-40B6-4DD6-968C-EE8AB5A809F4Q33477764-3CF89D5B-55E7-4E0C-A5A4-D29DED6B0C56Q33942884-2CB50681-61AD-488F-B2FD-71B7EA61B47FQ34076284-E4E03EE8-33A8-4308-A59E-52B6CF95CC9FQ34110227-8BEE9342-97E8-4A77-9E2F-99E2431310F8Q34995785-6A1FB929-4B72-4DC5-AF06-E94D78CC3C57Q35197124-FDF84E77-47E2-4211-A484-4A52891DF90CQ35604177-5860EB83-199B-4F9D-AC74-08675F51A066Q36245187-E97A825D-61FE-4245-B0E0-B89B630B21B3Q37062829-30F7A0CE-4E00-4F67-AD10-FB0ECA643007Q37086364-F5F038CA-8ED0-47EF-A3B0-69CBA9A0FE42Q37322106-3CDD1169-8E07-48F4-A214-2DE5F42AC39BQ38176899-66F36B8A-8B51-4AB5-93CA-89D040C52D28Q43267007-104191B7-08B9-4AFB-A2A0-73BA6D220A61Q53318965-74B7F0FB-40B7-41AF-8218-0432F709CA9C
P2860
Inhibition of glutaminyl cyclase prevents pGlu-Abeta formation after intracortical/hippocampal microinjection in vivo/in situ.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Inhibition of glutaminyl cycla ...... icroinjection in vivo/in situ.
@ast
Inhibition of glutaminyl cycla ...... icroinjection in vivo/in situ.
@en
type
label
Inhibition of glutaminyl cycla ...... icroinjection in vivo/in situ.
@ast
Inhibition of glutaminyl cycla ...... icroinjection in vivo/in situ.
@en
prefLabel
Inhibition of glutaminyl cycla ...... icroinjection in vivo/in situ.
@ast
Inhibition of glutaminyl cycla ...... icroinjection in vivo/in situ.
@en
P2093
P50
P1476
Inhibition of glutaminyl cycla ...... microinjection in vivo/in situ
@en
P2093
Daniel Friedrich
Hans-Ulrich Demuth
Katrin Schulz
Michael Wermann
Stephan Schilling
Thomas Appl
Torsten Hoffmann
Ulrich Heiser
Wolfgang Jagla
P2860
P304
P356
10.1111/J.1471-4159.2008.05471.X
P407
P577
2008-07-08T00:00:00Z